Healthcare Industry News: retractor
News Release - August 13, 2010
Integra LifeSciences Introduces the iPASSAGE(TM) Retractor for Minimally Invasive Spine SurgeryPLAINSBORO, N.J., Aug. 13, 2010 -- (Healthcare Sales & Marketing Network) -- Integra LifeSciences Holdings Corporation (Nasdaq:IART ) announced today the addition of the iPASSAGE(TM) retractor for Minimally Invasive Surgery (MIS) of the lumbar spine. The iPASSAGE(TM) retractor is a tissue sparing retraction system that allows the surgeon to make smaller incisions, potentially reducing tissue damage, blood loss and recovery time.
"We will continue to embrace and focus our product development on minimally invasive solutions," said John Winge, Executive Vice President of Sales and Marketing, Integra Spine. "Minutes matter when it comes to patient recovery time, and minimally invasive approaches may help decrease it."
To complement the iPASSAGE(TM) retractor, an MIS posterior discectomy preparation set is available for use with the Vu L-POD(TM) and Vu e-POD(TM) Intervertebral Body Fusion Device (IBD) systems. Additionally, the iPASSAGE(TM) retractor is compatible with the Paramount(R) MIS Pedicle Screw System and the Coral(TM) Spinal System's pedicle screws.
According to industry sources, the 2009 spinal minimally invasive market had an estimated value of $678 million in the United States.
The iPASSAGE(TM) retractor is distributed through Integra Spine, a leading provider of fusion implants and orthobiologics used in spinal surgery. Visit www.integraspine.com for more information.
Integra LifeSciences Holdings Corporation, a world leader in regenerative medicine, is a global medical device company dedicated to improving the quality of life for millions of patients every year. The company's products are used primarily in orthopedics, neurosurgery and general surgery. Headquartered in Plainsboro, New Jersey, Integra has research and manufacturing facilities throughout the world. Please visit www.integralife.com for more information.
This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements concerning the future use of the iPASSAGE(TM) retractor, Paramount(R) MIS Pedicle Screw System, Coral(TM) Spinal System, Vu e-POD(TM) device and Vu L-POD(TM) device. Such forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from predicted or expected results. Among other things, the willingness of physicians to use these products may affect the prospects for their use in clinical procedures. In addition, the economic, competitive, governmental, technological and other factors identified under the heading "Risk Factors" included in Item IA of Integra's Annual Report on Form 10-K for the year ended December 31, 2009 and information contained in subsequent filings with the Securities and Exchange Commission could affect actual results.
Source: Integra LifeSciences
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.